A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide against a placebo in adults with type 1 diabetes who also have obesity or are overweight to see how it affects their blood sugar levels.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 905 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-04 · est. completion 2026-12

Where 146 sites · Argentina, Brazil, Denmark, France, Germany, Israel, Italy, Japan, Mexico, Puerto Rico, Spain, United States

What this study is testing ClinicalTrials.gov NCT06914895 ↗

Description as written by the study sponsor.

The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change from Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 1 Diabetes, Obesity, Overweight
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06914895 ↗